Searchable abstracts of presentations at key conferences on calcified tissues

ba0001oc5.2 | Treatment of osteoporosis | ECTS2013

Fracture risk factors during treatment with denosumab

Cummings Steven , Feng Amy , Black Dennis , Wagman Rachel , Austin Matt , Wang Andrea , Walimbe Mona , Wu Lucy , Lui Lily , Vittinghoff Eric

Background: There are no models for estimating risk of fracture in patients taking treatments for osteoporosis. Knowing a patient’s risk of fracture during treatment may help make future treatment decisions; therefore, the development of on-treatment fracture risk models is needed.Methods: To assess on-treatment fracture risk, the analysis included subjects who received denosumab (DMAb) 60 mg Q6 every 6 months for at least 1 year in either FREEDOM o...

ba0001pp451 | Osteoporosis: treatment | ECTS2013

Estimation of vertebral and femoral strength during the first three years of denosumab therapy using an alternative smooth non-linear finite element methodology

Zysset Philippe , Pahr Dieter , Engelke Klaus , Genant Harry , McClung Michael , Kendler David , Recknor Christopher , Kinzl Michael , Schwiedrzik Jakob , Museyko Oleg , Wang Andrea , Libanati Cesar

Denosumab subcutaneous administration every 6 months reduced the incidence of new fractures in postmenopausal women with osteoporosis by 68% at the spine and 40% at the hip over 36 months compared with placebo in the FREEDOM study (Cummings et al., NEJM, 2009:361:756). This efficacy was supported by differential improvements from baseline in vertebral and femoral strength at 36 months (18.2 and 8.6%, respectively) estimated by an established voxel-based finit...

ba0003pp354 | Osteoporosis: treatment | ECTS2014

Denosumab treatment in women with osteoporosis reduces hip cortical porosity

Zebaze Roger M , Libanati Cesar , McClung Michael R , Zanchetta Jose R , Kendler David L , Hoiseth Arne , Wang Andrea , Ghasem-Zadeh Ali , Seeman Ego

Bone strength is influenced by cortical thickness, area, mass and porosity, all of which contribute to nonvertebral fracture risk. Cortical porosity is one parameter of structural decay associated with bone fragility. This is caused by unbalanced and accelerated remodelling of Haversian units which enlarge, coalesce and fragment the cortex. Antiresorptive therapies will limit progression of cortical porosity; reducing existing porosity would be a goal for those already at incr...

ba0005oc3.2 | Clinical trials, FGF-23 and focal osteoporosis | ECTS2016

Effects of Denosumab (Dmab) on bone matrix mineralization: results from the phase 3 FREEDOM trial

Dempster David W , Brown Jacques P , Yue Susan , Farlay Delphine , Rizzo Sebastien , Song Jenny , Wang Andrea , Wagman Rachel B , Boivin Georges

Low fracture (FX) incidence has been demonstrated in women with postmenopausal osteoporosis (PMO) treated with DMAb for up to 10 years in the FREEDOM extension [Bone ASBMR 2015]. Bone biopsy-based assessment of DMAb’s effects at the tissue level has demonstrated a low remodelling rate consistent with DMAb’s mechanism of action (Reid JBMR 2010; Brown JBMR 2014). From FREEDOM, we report the effects of DMAb on bone matrix mineralization in women who un...